CBIO
NASDAQ
US
Crescent Biopharma, Inc. - Common Stock
$19,40
▲ +$0,08
(+0,41%)
Vol. 209K
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$164.8M
ROE
-230,8%
Margine
-90786,4%
D/E
0,00
Beta
-5,10
52W
$10–$21
Consenso Wall Street
15 analisti · Apr 20266
Acquisto forte
8
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
PROK
Prokidney Corp
$673.9M
TECX
Tectonic Therapeutic Inc
$390.4M
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
ZURA
Zura Bio Ltd
$340.7M
UPB
Upstream Bio Inc
$1.5B
RIGL
Rigel Pharmaceuticals Inc
P/E 6,9
$777.4M
LRMR
Larimar Therapeutics Inc
$326.1M
TRDA
Entrada Therapeutics Inc
$392.9M
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-2,57 | $-0,54 | +$2,03 |
| Set 2025 | $-2,02 | $-1,27 | +$0,75 |
| Giu 2025 | $-1,80 | $-4,93 | $-3,13 |
| Mar 2025 | $-5,10 | $-4,00 | +$1,10 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|
| Ricavi | — | — | — | $10.8M |
| Utile netto | -$17.9M | -$21.8M | -$24.6M | -$92.4M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -230.8% | -230.8% | -230.8% | -230.8% | -230.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -90786.4% | -90786.4% | -90786.4% | -90786.4% | -90786.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.21 | 2.29 | 2.29 | 9.21 | 6.63 | 6.63 |
Rapporti chiave
ROA (TTM)
-177,4%
P/S (TTM)
16476,52
P/B
0,4
EPS (TTM)
$-42,26
CF/Share
$-1,37
52W High
$21,40
52W Low
$9,81
$9,81
Intervallo 52 settimane
$21,40
Salute finanziaria
Flusso di cassa libero
-$98.9M
Debito netto
-$211.5M
Liquidità
$213.2M
Debito totale
$1.6M
Aggiornato al Dic 31, 2025
Як CBIO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CBIO vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
16476,5
▲
128122%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
0,4
▼
84%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CBIO vs аналоги Biotechnology
ROE
-230,8%
▼
243%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-90786,4%
▼
31560%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-177,4%
▼
280%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя CBIO vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
6,6
▲
49%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
-5,1
▼
626%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CBIO
CBIO
Mediana peer
Industria
CBIO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CBIO vs аналоги: ключові метрики
Principali azionisti
Top 5: 48,77%FMR, LLC
15,00%
$62.7M
BVF Inc.
9,97%
$41.7M
Fairmount Funds Management …
9,97%
$41.7M
VR Adviser, LLC
7,74%
$32.3M
FCPM III Services B.V.
6,09%
$25.4M
Aggiornato al Dic 31, 2025
Dividendi
$167,00
/ anno
Gen 13, 2023
$24,0000
Set 21, 2022
$143,0000
Ultime notizie
Nessuna notizia correlata ancora